Nordicus Partners CORP 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OQB
Nordicus Partners reports increased net losses for the nine months ended December 31, 2025, despite significant R&D progress in its biotech portfolio and a substantial cash infusion from financing activities.
OQB
Nordicus Partners Corporation reported a significant increase in net loss for the six months ended September 30, 2025, as it continues to expand its preclinical biotechnology portfolio and address going concern issues.
OQB
Nordicus Partners Corporation reported a significant increase in net loss for the quarter ended June 30, 2025, driven by higher operating expenses and investment losses, despite positive preclinical developments for its portfolio companies.
OQB
10-Q: Nordicus Partners Corporation Reports Q3 Results, Completes Acquisitions of Orocidin and Bio-Convert
Nordicus Partners Corporation files its quarterly report, highlighting acquisitions and financial results for the period ending December 31, 2024.
OQB
Nordicus Partners Corporation reported a significant increase in net loss for the second quarter of 2025, driven by increased operating expenses and the impact of recent acquisitions.
OQB
10-Q: Nordicus Partners Corporation Reports Increased Net Loss in Q1 2025 Following Orocidin Acquisition
Nordicus Partners Corporation reported a net loss of $258,169 for the quarter ended June 30, 2024, primarily due to increased operating expenses and the acquisition of Orocidin A/S.
OQB
Nordicus Partners Corporation reported a net loss of $74,990 for the three months ended December 31, 2023, a significant decrease compared to the $850,609 loss in the same period of 2022.